{"gene":"AP2S1","run_date":"2026-06-09T22:02:43","timeline":{"discoveries":[{"year":2012,"finding":"AP2S1 encodes the σ2 subunit of the AP2 heterotetramer (α, β, μ, σ), which links clathrin to vesicle membranes and binds tyrosine- and dileucine-based motifs of membrane-associated cargo proteins during clathrin-mediated endocytosis. Missense mutations at Arg15 of AP2σ2, which forms key contacts with dileucine-based motifs of CCV cargo proteins, impair CaSR endocytosis, reduce CaSR-mediated intracellular signaling, and decrease sensitivity of CaSR-expressing cells to extracellular calcium, likely through loss of interaction with a C-terminal CaSR dileucine-based motif.","method":"Cellular expression assays, CaSR endocytosis assays, calcium signaling assays in CaSR-expressing cells, mutational analysis of the CaSR dileucine motif","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal functional assays (endocytosis, signaling, ligand-motif interaction), replicated across subsequent independent studies","pmids":["23222959"],"is_preprint":false},{"year":1996,"finding":"The human AP2S1 gene (symbol CLAPS2) encodes AP17, the small (sigma) chain of the clathrin-associated AP-2 complex, and maps to chromosome 19q13.2→q13.3.","method":"cDNA cloning, chromosomal assignment by fluorescence in situ hybridization","journal":"Cytogenetics and cell genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct molecular cloning and chromosomal mapping, single lab but two orthogonal methods","pmids":["9040778"],"is_preprint":false},{"year":1998,"finding":"AP2S1 (CLAPS2) undergoes alternative splicing to produce a variant transcript encoding AP17Δ, a 142 aa protein lacking 38 aa of the canonical AP17; both transcripts are expressed in leukocytes and leukemia cells.","method":"cDNA library screening, complete coding sequence determination, RT-PCR with variant-specific primers","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct molecular characterization of alternative transcript, single lab with two orthogonal methods","pmids":["9767099"],"is_preprint":false},{"year":2017,"finding":"ENU-induced deletion of 17 evolutionarily conserved amino acids forming part of the AP2σ α1-helix, α1-β3 loop, and β3 strand (del17 splice-site variant) results in a non-functional AP2σ. Homozygous Ap2s1 knockout mice are non-viable and die between embryonic days 3.5 and 9.5, demonstrating that AP2σ is essential for embryonic patterning and organogenesis. Heterozygous mice are haplosufficient with normal calcium homeostasis.","method":"ENU mutagenesis screen, 3D structural modeling, cellular expression of missense variants, CaSR-mediated signaling assays, in vivo mouse phenotyping (plasma biochemistry, urinary excretion, hormone measurements)","journal":"JBMR plus","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic model with multiple biochemical phenotypic readouts, structural modeling, and signaling assays in single rigorous study","pmids":["29479578"],"is_preprint":false},{"year":2021,"finding":"The AP2S1 p.Arg15Leu mutation impairs protein-protein interactions between AP2σ2 and the other AP2 complex subunits (AP2α, AP2β2, AP2μ2), and also reduces the AP2σ2–CaSR interaction, as demonstrated by co-immunoprecipitation. CRISPR/Cas9 knock-in mice harboring p.Arg15Leu recapitulate FHH3 with hypercalcaemia, hypermagnesaemia, and hypophosphataemia; cinacalcet reduced plasma calcium and PTH in these mice but did not restore the diminished AP2σ2–CaSR interaction in vitro.","method":"CRISPR/Cas9 knock-in mouse generation, co-immunoprecipitation (AP2σ2 with AP2 subunits and CaSR), in vivo plasma biochemistry, cinacalcet treatment of mice, in vitro signaling assay","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, CRISPR in vivo model with multiple biochemical readouts, pharmacological rescue, single paper with multiple orthogonal methods","pmids":["33729479"],"is_preprint":false},{"year":2022,"finding":"AP2S1 regulates the degradation of amyloid precursor protein (APP) through a mechanism involving late endosome (LE)-to-lysosome fusion rather than endocytosis per se. Knockdown of AP2S1 promoted translocation of APP from RAB9-positive late endosomes to LAMP1-positive lysosomes and enhanced LE-lysosome fusion; this was prevented by silencing VPS41, a component required for LE-lysosome fusion. AAV-mediated AP2S1 knockdown in hippocampus of APP/PS1 mice reduced APP and Aβ levels and improved cognitive function.","method":"siRNA knockdown and overexpression in APP695-expressing cells, confocal morphological colocalization (RAB9, LAMP1 markers), VPS41 co-knockdown epistasis, AAV-mediated shRNA delivery in APP/PS1 mice, Western blotting, cognitive behavioral assays","journal":"Traffic (Copenhagen, Denmark)","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (VPS41 rescue), multiple orthogonal methods (cell and in vivo), functional phenotypic readout; single lab but rigorous","pmids":["36412210"],"is_preprint":false},{"year":2024,"finding":"Five AP2S1 variants at residues other than Arg15 (p.Arg10Trp, p.Arg10Gln, p.Lys18Glu, p.Lys18Asn, p.Arg61His) decrease cell viability, reduce clathrin-mediated endocytosis (transferrin uptake assay), and disrupt interactions between AP2σ2 and other AP2 complex subunits, thereby impairing AP2 complex formation. The p.Arg10Trp variant additionally shows reduced interactions with 44 human proteins including intersectin-1, a component required for clathrin-coated pit formation and synaptic vesicle dynamics.","method":"Cell viability assays, transferrin uptake CME assay, co-immunoprecipitation of AP2 subunits, quantitative proteomics/interaction profiling (mass spectrometry with intersectin-1)","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal functional methods (CME assay, Co-IP, proteomics), preprint not yet peer-reviewed, single lab","pmids":["bio_10.1101_2024.07.22.24310683"],"is_preprint":true}],"current_model":"AP2S1 encodes the σ2 (AP2σ2/AP17) subunit of the heterotetrameric AP2 clathrin adaptor complex (α/β2/μ2/σ2), where Arg15 on AP2σ2 forms critical contacts with dileucine-based motifs of cargo proteins (including the CaSR) to drive clathrin-mediated endocytosis; loss-of-function mutations at Arg15 impair AP2σ2 interactions with both the other AP2 subunits and CaSR, reducing CaSR internalization and downstream calcium signaling to cause familial hypocalciuric hypercalcemia type 3, while AP2S1 also regulates APP degradation via a late endosome–lysosome fusion mechanism independent of endocytosis, and is essential for embryonic viability."},"narrative":{"mechanistic_narrative":"AP2S1 encodes the σ2 (AP17) subunit of the heterotetrameric AP2 clathrin adaptor complex, which links clathrin to the plasma membrane and recognizes tyrosine- and dileucine-based sorting motifs of cargo proteins during clathrin-mediated endocytosis [PMID:23222959, PMID:9040778]. Within the assembled complex, Arg15 of AP2σ2 contacts the dileucine motif of cargo, and missense mutations at this residue impair both AP2σ2 association with the other AP2 subunits (AP2α, AP2β2, AP2μ2) and its interaction with the calcium-sensing receptor (CaSR), reducing CaSR endocytosis and CaSR-mediated calcium signaling [PMID:23222959, PMID:33729479]. These loss-of-function mutations cause familial hypocalciuric hypercalcemia type 3, recapitulated in Arg15Leu knock-in mice that display hypercalcaemia, hypermagnesaemia, and hypophosphataemia [PMID:33729479]. The cargo-adaptor role extends beyond Arg15: variants at Arg10, Lys18, and Arg61 likewise disrupt AP2 complex formation and reduce general clathrin-mediated endocytosis [PMID:bio_10.1101_2024.07.22.24310683]. Independent of its endocytic function, AP2S1 also restrains amyloid precursor protein (APP) degradation by limiting RAB9-positive late endosome-to-LAMP1-positive lysosome fusion via VPS41, such that its depletion lowers APP and Aβ levels [PMID:36412210]. AP2σ2 is essential for development, as homozygous Ap2s1 loss is embryonic lethal while heterozygotes are haplosufficient [PMID:29479578].","teleology":[{"year":1996,"claim":"Established the molecular identity of AP2S1 as the small σ chain of the clathrin-associated AP-2 complex, placing it within the endocytic machinery.","evidence":"cDNA cloning and FISH chromosomal mapping to 19q13.2→q13.3","pmids":["9040778"],"confidence":"Medium","gaps":["No functional assay of the encoded protein","Cargo specificity and complex assembly not addressed"]},{"year":1998,"claim":"Showed AP2S1 produces an alternatively spliced shorter isoform (AP17Δ) expressed alongside the canonical transcript, raising the possibility of isoform-specific function.","evidence":"cDNA library screening and variant-specific RT-PCR in leukocytes and leukemia cells","pmids":["9767099"],"confidence":"Medium","gaps":["Functional consequence of the 38-aa deletion unknown","No evidence the isoform incorporates into AP2 complexes"]},{"year":2012,"claim":"Linked AP2σ2 cargo-recognition function to a human disease by showing Arg15 mutations impair CaSR endocytosis and calcium signaling, defining the cargo-motif contact mechanism.","evidence":"Cellular endocytosis and calcium-signaling assays in CaSR-expressing cells with CaSR dileucine-motif mutational analysis","pmids":["23222959"],"confidence":"High","gaps":["Direct biochemical demonstration of AP2σ2–CaSR motif binding not yet shown","Effect on other AP2 subunit interactions not tested"]},{"year":2017,"claim":"Demonstrated AP2σ2 is essential for embryonic development and that a single functional allele suffices for normal calcium homeostasis, distinguishing dosage requirements from FHH3 dominant-negative effects.","evidence":"ENU mutagenesis, structural modeling, and in vivo mouse phenotyping of knockout and heterozygous animals","pmids":["29479578"],"confidence":"High","gaps":["Tissue-specific developmental roles not resolved","Mechanism of embryonic lethality not defined"]},{"year":2021,"claim":"Provided reciprocal biochemical proof that the Arg15Leu mutation weakens both AP2 intra-complex assembly and AP2σ2–CaSR binding, and modeled FHH3 in vivo with pharmacological intervention.","evidence":"CRISPR/Cas9 knock-in mice, co-immunoprecipitation of AP2 subunits and CaSR, plasma biochemistry, and cinacalcet treatment","pmids":["33729479"],"confidence":"High","gaps":["Cinacalcet did not restore the AP2σ2–CaSR interaction, leaving the molecular defect uncorrected","Structural basis of disrupted assembly not solved"]},{"year":2022,"claim":"Uncovered an endocytosis-independent role in which AP2S1 limits APP degradation by restraining late endosome-to-lysosome fusion, implicating it in amyloid handling.","evidence":"siRNA knockdown/overexpression with RAB9/LAMP1 colocalization, VPS41 epistasis, and AAV-shRNA delivery in APP/PS1 mice with cognitive assays","pmids":["36412210"],"confidence":"High","gaps":["How AP2S1 mechanistically controls LE-lysosome fusion is undefined","Relationship between this role and canonical AP2 function unclear"]},{"year":2024,"claim":"Extended the cargo-adaptor mechanism beyond Arg15 by showing additional surface residues are required for AP2 complex assembly and general clathrin-mediated endocytosis.","evidence":"Transferrin uptake CME assay, Co-IP of AP2 subunits, and quantitative interaction proteomics (preprint)","pmids":["bio_10.1101_2024.07.22.24310683"],"confidence":"Medium","gaps":["Preprint not yet peer-reviewed","Functional role of the intersectin-1 interaction not validated","Clinical correlation of these variants not established"]},{"year":null,"claim":"How AP2S1's canonical endocytic adaptor function and its endosome-lysosome fusion role are mechanistically coordinated, and the structural basis of cargo-motif recognition, remain open.","evidence":"","pmids":[],"confidence":"High","gaps":["No high-resolution structure of AP2σ2 bound to a cargo dileucine motif in the timeline","Whether the APP/fusion role requires the assembled AP2 complex is unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,4,6]},{"term_id":"GO:0038024","term_label":"cargo receptor activity","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[5]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[5]}],"pathway":[{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[0,6]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,4]}],"complexes":["AP2 adaptor complex"],"partners":["AP2A1","AP2B1","AP2M1","CASR","VPS41","ITSN1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P53680","full_name":"AP-2 complex subunit sigma","aliases":["Adaptor protein complex AP-2 subunit sigma","Adaptor-related protein complex 2 subunit sigma","Clathrin assembly protein 2 sigma small chain","Clathrin coat assembly protein AP17","Clathrin coat-associated protein AP17","HA2 17 kDa subunit","Plasma membrane adaptor AP-2 17 kDa protein","Sigma2-adaptin"],"length_aa":142,"mass_kda":17.0,"function":"Component of the adaptor protein complex 2 (AP-2). Adaptor protein complexes function in protein transport via transport vesicles in different membrane traffic pathways. Adaptor protein complexes are vesicle coat components and appear to be involved in cargo selection and vesicle formation. AP-2 is involved in clathrin-dependent endocytosis in which cargo proteins are incorporated into vesicles surrounded by clathrin (clathrin-coated vesicles, CCVs) which are destined for fusion with the early endosome. The clathrin lattice serves as a mechanical scaffold but is itself unable to bind directly to membrane components. Clathrin-associated adaptor protein (AP) complexes which can bind directly to both the clathrin lattice and to the lipid and protein components of membranes are considered to be the major clathrin adaptors contributing the CCV formation. AP-2 also serves as a cargo receptor to selectively sort the membrane proteins involved in receptor-mediated endocytosis. AP-2 seems to play a role in the recycling of synaptic vesicle membranes from the presynaptic surface. AP-2 recognizes Y-X-X-[FILMV] (Y-X-X-Phi) and [ED]-X-X-X-L-[LI] endocytosis signal motifs within the cytosolic tails of transmembrane cargo molecules. AP-2 may also play a role in maintaining normal post-endocytic trafficking through the ARF6-regulated, non-clathrin pathway. The AP-2 alpha and AP-2 sigma subunits are thought to contribute to the recognition of the [ED]-X-X-X-L-[LI] motif (By similarity). May also play a role in extracellular calcium homeostasis","subcellular_location":"Cell membrane; Membrane, coated pit","url":"https://www.uniprot.org/uniprotkb/P53680/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/AP2S1","classification":"Common Essential","n_dependent_lines":924,"n_total_lines":1208,"dependency_fraction":0.7649006622516556},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000042753","cell_line_id":"CID001745","localizations":[{"compartment":"membrane","grade":3},{"compartment":"cytoplasmic","grade":1}],"interactors":[{"gene":"AP2B1","stoichiometry":10.0},{"gene":"AP2A2","stoichiometry":10.0},{"gene":"AP2M1","stoichiometry":10.0},{"gene":"C15ORF57","stoichiometry":10.0},{"gene":"AP2A1","stoichiometry":4.0},{"gene":"EPS15","stoichiometry":4.0},{"gene":"HIST1H1B","stoichiometry":4.0},{"gene":"FCHO2","stoichiometry":4.0},{"gene":"AAGAB","stoichiometry":4.0},{"gene":"NECAP2","stoichiometry":4.0}],"url":"https://opencell.sf.czbiohub.org/target/CID001745","total_profiled":1310},"omim":[{"mim_id":"602242","title":"ADAPTOR-RELATED PROTEIN COMPLEX 2, SIGMA-1 SUBUNIT; AP2S1","url":"https://www.omim.org/entry/602242"},{"mim_id":"600740","title":"HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3","url":"https://www.omim.org/entry/600740"},{"mim_id":"145981","title":"HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE II; HHC2","url":"https://www.omim.org/entry/145981"},{"mim_id":"145980","title":"HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1","url":"https://www.omim.org/entry/145980"},{"mim_id":"139313","title":"GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-11; GNA11","url":"https://www.omim.org/entry/139313"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/AP2S1"},"hgnc":{"alias_symbol":["FBHOk","FBH3"],"prev_symbol":["CLAPS2","HHC3"]},"alphafold":{"accession":"P53680","domains":[{"cath_id":"3.30.450.60","chopping":"1-140","consensus_level":"medium","plddt":97.3816,"start":1,"end":140}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P53680","model_url":"https://alphafold.ebi.ac.uk/files/AF-P53680-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P53680-F1-predicted_aligned_error_v6.png","plddt_mean":97.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=AP2S1","jax_strain_url":"https://www.jax.org/strain/search?query=AP2S1"},"sequence":{"accession":"P53680","fasta_url":"https://rest.uniprot.org/uniprotkb/P53680.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P53680/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P53680"}},"corpus_meta":[{"pmid":"23222959","id":"PMC_23222959","title":"Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3.","date":"2012","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23222959","citation_count":191,"is_preprint":false},{"pmid":"9915958","id":"PMC_9915958","title":"Localization of familial benign hypercalcemia, Oklahoma variant (FBHOk), to chromosome 19q13.","date":"1999","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9915958","citation_count":85,"is_preprint":false},{"pmid":"24731014","id":"PMC_24731014","title":"Codon Arg15 mutations of the AP2S1 gene: common occurrence in familial hypocalciuric hypercalcemia cases negative for calcium-sensing receptor (CASR) mutations.","date":"2014","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24731014","citation_count":33,"is_preprint":false},{"pmid":"25993639","id":"PMC_25993639","title":"Cinacalcet Treatment in an Adolescent With Concurrent 22q11.2 Deletion Syndrome and Familial Hypocalciuric Hypercalcemia Type 3 Caused by AP2S1 Mutation.","date":"2015","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25993639","citation_count":20,"is_preprint":false},{"pmid":"28176280","id":"PMC_28176280","title":"Stepwise CaSR, AP2S1, and GNA11 sequencing in patients with suspected familial hypocalciuric hypercalcemia.","date":"2017","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/28176280","citation_count":18,"is_preprint":false},{"pmid":"29479578","id":"PMC_29479578","title":"N-ethyl-N-nitrosourea-Induced Adaptor Protein 2 Sigma Subunit 1 (Ap2s1) Mutations Establish Ap2s1 Loss-of-Function Mice.","date":"2017","source":"JBMR plus","url":"https://pubmed.ncbi.nlm.nih.gov/29479578","citation_count":16,"is_preprint":false},{"pmid":"27913609","id":"PMC_27913609","title":"AP2S1 and GNA11 mutations - not a common cause of familial hypocalciuric hypercalcemia.","date":"2016","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27913609","citation_count":16,"is_preprint":false},{"pmid":"24081735","id":"PMC_24081735","title":"Identification of AP2S1 mutation and effects of low calcium formula in an infant with hypercalcemia and hypercalciuria.","date":"2013","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24081735","citation_count":16,"is_preprint":false},{"pmid":"33729479","id":"PMC_33729479","title":"Ap2s1 mutation causes hypercalcaemia in mice and impairs interaction between calcium-sensing receptor and adaptor protein-2.","date":"2021","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33729479","citation_count":15,"is_preprint":false},{"pmid":"36412210","id":"PMC_36412210","title":"AP2S1 regulates APP degradation through late endosome-lysosome fusion in cells and APP/PS1 mice.","date":"2022","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/36412210","citation_count":15,"is_preprint":false},{"pmid":"24708097","id":"PMC_24708097","title":"Mutational analysis of the adaptor protein 2 sigma subunit (AP2S1) gene: search for autosomal dominant hypocalcemia type 3 (ADH3).","date":"2014","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24708097","citation_count":12,"is_preprint":false},{"pmid":"24423332","id":"PMC_24423332","title":"Analysis of AP2S1, a calcium-sensing receptor regulator, in familial and sporadic isolated hypoparathyroidism.","date":"2014","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24423332","citation_count":7,"is_preprint":false},{"pmid":"32047691","id":"PMC_32047691","title":"Clinical and Biochemical Features in a Case of Familial Hypocalciuric Hypercalcemia Type 3 with AP2S1 Gene Mutation in Codon Arg15His.","date":"2020","source":"Case reports in pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/32047691","citation_count":6,"is_preprint":false},{"pmid":"31391146","id":"PMC_31391146","title":"Cinacalcet sustainedly prevents pancreatitis in a child with a compound heterozygous SPINK1/AP2S1 mutation.","date":"2019","source":"Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/31391146","citation_count":6,"is_preprint":false},{"pmid":"31723423","id":"PMC_31723423","title":"A Hong Kong Chinese kindred with familial hypocalciuric hypercalcaemia caused by AP2S1 mutation.","date":"2019","source":"F1000Research","url":"https://pubmed.ncbi.nlm.nih.gov/31723423","citation_count":4,"is_preprint":false},{"pmid":"9040778","id":"PMC_9040778","title":"Human CLAPS2 encoding AP17, a small chain of the clathrin-associated protein complex: cDNA cloning and chromosomal assignment to 19q13.2-->q13.3.","date":"1996","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9040778","citation_count":4,"is_preprint":false},{"pmid":"9767099","id":"PMC_9767099","title":"A novel spliced transcript of human CLAPS2 encoding a protein alternative to clathrin adaptor protein AP17.","date":"1998","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/9767099","citation_count":2,"is_preprint":false},{"pmid":"33168530","id":"PMC_33168530","title":"Familial hypocalciuric hypercalcaemia type 3: AP2S1 missense mutation.","date":"2020","source":"BMJ case reports","url":"https://pubmed.ncbi.nlm.nih.gov/33168530","citation_count":1,"is_preprint":false},{"pmid":"39949382","id":"PMC_39949382","title":"Successful Treatment With Evocalcet Against Familial Hypocalciuric Hypercalcemia Type 3 (FHH3) Identified by AP2S1 Gene Mutation (p.Arg15Leu).","date":"2025","source":"Case reports in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/39949382","citation_count":0,"is_preprint":false},{"pmid":"42253998","id":"PMC_42253998","title":"Single-cell extracellular vesicle-program scoring maps immunometabolic rewiring and immune crosstalk of mesenchymal stromal cells in intervertebral disc degeneration, prioritizing AP2S1 and CSTB.","date":"2026","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/42253998","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.07.22.24310683","title":"Adaptor protein 2 sigma subunit (<i>AP2S1</i>) variants associated with neurodevelopmental disorders","date":"2024-07-22","source":"bioRxiv","url":"https://doi.org/10.1101/2024.07.22.24310683","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":12818,"output_tokens":2263,"usd":0.0362,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9373,"output_tokens":2754,"usd":0.057857,"stage2_stop_reason":"end_turn"},"total_usd":0.094057,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2012,\n      \"finding\": \"AP2S1 encodes the σ2 subunit of the AP2 heterotetramer (α, β, μ, σ), which links clathrin to vesicle membranes and binds tyrosine- and dileucine-based motifs of membrane-associated cargo proteins during clathrin-mediated endocytosis. Missense mutations at Arg15 of AP2σ2, which forms key contacts with dileucine-based motifs of CCV cargo proteins, impair CaSR endocytosis, reduce CaSR-mediated intracellular signaling, and decrease sensitivity of CaSR-expressing cells to extracellular calcium, likely through loss of interaction with a C-terminal CaSR dileucine-based motif.\",\n      \"method\": \"Cellular expression assays, CaSR endocytosis assays, calcium signaling assays in CaSR-expressing cells, mutational analysis of the CaSR dileucine motif\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal functional assays (endocytosis, signaling, ligand-motif interaction), replicated across subsequent independent studies\",\n      \"pmids\": [\"23222959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The human AP2S1 gene (symbol CLAPS2) encodes AP17, the small (sigma) chain of the clathrin-associated AP-2 complex, and maps to chromosome 19q13.2→q13.3.\",\n      \"method\": \"cDNA cloning, chromosomal assignment by fluorescence in situ hybridization\",\n      \"journal\": \"Cytogenetics and cell genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct molecular cloning and chromosomal mapping, single lab but two orthogonal methods\",\n      \"pmids\": [\"9040778\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"AP2S1 (CLAPS2) undergoes alternative splicing to produce a variant transcript encoding AP17Δ, a 142 aa protein lacking 38 aa of the canonical AP17; both transcripts are expressed in leukocytes and leukemia cells.\",\n      \"method\": \"cDNA library screening, complete coding sequence determination, RT-PCR with variant-specific primers\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct molecular characterization of alternative transcript, single lab with two orthogonal methods\",\n      \"pmids\": [\"9767099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ENU-induced deletion of 17 evolutionarily conserved amino acids forming part of the AP2σ α1-helix, α1-β3 loop, and β3 strand (del17 splice-site variant) results in a non-functional AP2σ. Homozygous Ap2s1 knockout mice are non-viable and die between embryonic days 3.5 and 9.5, demonstrating that AP2σ is essential for embryonic patterning and organogenesis. Heterozygous mice are haplosufficient with normal calcium homeostasis.\",\n      \"method\": \"ENU mutagenesis screen, 3D structural modeling, cellular expression of missense variants, CaSR-mediated signaling assays, in vivo mouse phenotyping (plasma biochemistry, urinary excretion, hormone measurements)\",\n      \"journal\": \"JBMR plus\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic model with multiple biochemical phenotypic readouts, structural modeling, and signaling assays in single rigorous study\",\n      \"pmids\": [\"29479578\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The AP2S1 p.Arg15Leu mutation impairs protein-protein interactions between AP2σ2 and the other AP2 complex subunits (AP2α, AP2β2, AP2μ2), and also reduces the AP2σ2–CaSR interaction, as demonstrated by co-immunoprecipitation. CRISPR/Cas9 knock-in mice harboring p.Arg15Leu recapitulate FHH3 with hypercalcaemia, hypermagnesaemia, and hypophosphataemia; cinacalcet reduced plasma calcium and PTH in these mice but did not restore the diminished AP2σ2–CaSR interaction in vitro.\",\n      \"method\": \"CRISPR/Cas9 knock-in mouse generation, co-immunoprecipitation (AP2σ2 with AP2 subunits and CaSR), in vivo plasma biochemistry, cinacalcet treatment of mice, in vitro signaling assay\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, CRISPR in vivo model with multiple biochemical readouts, pharmacological rescue, single paper with multiple orthogonal methods\",\n      \"pmids\": [\"33729479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"AP2S1 regulates the degradation of amyloid precursor protein (APP) through a mechanism involving late endosome (LE)-to-lysosome fusion rather than endocytosis per se. Knockdown of AP2S1 promoted translocation of APP from RAB9-positive late endosomes to LAMP1-positive lysosomes and enhanced LE-lysosome fusion; this was prevented by silencing VPS41, a component required for LE-lysosome fusion. AAV-mediated AP2S1 knockdown in hippocampus of APP/PS1 mice reduced APP and Aβ levels and improved cognitive function.\",\n      \"method\": \"siRNA knockdown and overexpression in APP695-expressing cells, confocal morphological colocalization (RAB9, LAMP1 markers), VPS41 co-knockdown epistasis, AAV-mediated shRNA delivery in APP/PS1 mice, Western blotting, cognitive behavioral assays\",\n      \"journal\": \"Traffic (Copenhagen, Denmark)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (VPS41 rescue), multiple orthogonal methods (cell and in vivo), functional phenotypic readout; single lab but rigorous\",\n      \"pmids\": [\"36412210\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Five AP2S1 variants at residues other than Arg15 (p.Arg10Trp, p.Arg10Gln, p.Lys18Glu, p.Lys18Asn, p.Arg61His) decrease cell viability, reduce clathrin-mediated endocytosis (transferrin uptake assay), and disrupt interactions between AP2σ2 and other AP2 complex subunits, thereby impairing AP2 complex formation. The p.Arg10Trp variant additionally shows reduced interactions with 44 human proteins including intersectin-1, a component required for clathrin-coated pit formation and synaptic vesicle dynamics.\",\n      \"method\": \"Cell viability assays, transferrin uptake CME assay, co-immunoprecipitation of AP2 subunits, quantitative proteomics/interaction profiling (mass spectrometry with intersectin-1)\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal functional methods (CME assay, Co-IP, proteomics), preprint not yet peer-reviewed, single lab\",\n      \"pmids\": [\"bio_10.1101_2024.07.22.24310683\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"AP2S1 encodes the σ2 (AP2σ2/AP17) subunit of the heterotetrameric AP2 clathrin adaptor complex (α/β2/μ2/σ2), where Arg15 on AP2σ2 forms critical contacts with dileucine-based motifs of cargo proteins (including the CaSR) to drive clathrin-mediated endocytosis; loss-of-function mutations at Arg15 impair AP2σ2 interactions with both the other AP2 subunits and CaSR, reducing CaSR internalization and downstream calcium signaling to cause familial hypocalciuric hypercalcemia type 3, while AP2S1 also regulates APP degradation via a late endosome–lysosome fusion mechanism independent of endocytosis, and is essential for embryonic viability.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"AP2S1 encodes the σ2 (AP17) subunit of the heterotetrameric AP2 clathrin adaptor complex, which links clathrin to the plasma membrane and recognizes tyrosine- and dileucine-based sorting motifs of cargo proteins during clathrin-mediated endocytosis [#0, #1]. Within the assembled complex, Arg15 of AP2σ2 contacts the dileucine motif of cargo, and missense mutations at this residue impair both AP2σ2 association with the other AP2 subunits (AP2α, AP2β2, AP2μ2) and its interaction with the calcium-sensing receptor (CaSR), reducing CaSR endocytosis and CaSR-mediated calcium signaling [#0, #4]. These loss-of-function mutations cause familial hypocalciuric hypercalcemia type 3, recapitulated in Arg15Leu knock-in mice that display hypercalcaemia, hypermagnesaemia, and hypophosphataemia [#4]. The cargo-adaptor role extends beyond Arg15: variants at Arg10, Lys18, and Arg61 likewise disrupt AP2 complex formation and reduce general clathrin-mediated endocytosis [#6]. Independent of its endocytic function, AP2S1 also restrains amyloid precursor protein (APP) degradation by limiting RAB9-positive late endosome-to-LAMP1-positive lysosome fusion via VPS41, such that its depletion lowers APP and Aβ levels [#5]. AP2σ2 is essential for development, as homozygous Ap2s1 loss is embryonic lethal while heterozygotes are haplosufficient [#3].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established the molecular identity of AP2S1 as the small σ chain of the clathrin-associated AP-2 complex, placing it within the endocytic machinery.\",\n      \"evidence\": \"cDNA cloning and FISH chromosomal mapping to 19q13.2→q13.3\",\n      \"pmids\": [\"9040778\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional assay of the encoded protein\", \"Cargo specificity and complex assembly not addressed\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Showed AP2S1 produces an alternatively spliced shorter isoform (AP17Δ) expressed alongside the canonical transcript, raising the possibility of isoform-specific function.\",\n      \"evidence\": \"cDNA library screening and variant-specific RT-PCR in leukocytes and leukemia cells\",\n      \"pmids\": [\"9767099\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of the 38-aa deletion unknown\", \"No evidence the isoform incorporates into AP2 complexes\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Linked AP2σ2 cargo-recognition function to a human disease by showing Arg15 mutations impair CaSR endocytosis and calcium signaling, defining the cargo-motif contact mechanism.\",\n      \"evidence\": \"Cellular endocytosis and calcium-signaling assays in CaSR-expressing cells with CaSR dileucine-motif mutational analysis\",\n      \"pmids\": [\"23222959\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical demonstration of AP2σ2–CaSR motif binding not yet shown\", \"Effect on other AP2 subunit interactions not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrated AP2σ2 is essential for embryonic development and that a single functional allele suffices for normal calcium homeostasis, distinguishing dosage requirements from FHH3 dominant-negative effects.\",\n      \"evidence\": \"ENU mutagenesis, structural modeling, and in vivo mouse phenotyping of knockout and heterozygous animals\",\n      \"pmids\": [\"29479578\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific developmental roles not resolved\", \"Mechanism of embryonic lethality not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Provided reciprocal biochemical proof that the Arg15Leu mutation weakens both AP2 intra-complex assembly and AP2σ2–CaSR binding, and modeled FHH3 in vivo with pharmacological intervention.\",\n      \"evidence\": \"CRISPR/Cas9 knock-in mice, co-immunoprecipitation of AP2 subunits and CaSR, plasma biochemistry, and cinacalcet treatment\",\n      \"pmids\": [\"33729479\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cinacalcet did not restore the AP2σ2–CaSR interaction, leaving the molecular defect uncorrected\", \"Structural basis of disrupted assembly not solved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Uncovered an endocytosis-independent role in which AP2S1 limits APP degradation by restraining late endosome-to-lysosome fusion, implicating it in amyloid handling.\",\n      \"evidence\": \"siRNA knockdown/overexpression with RAB9/LAMP1 colocalization, VPS41 epistasis, and AAV-shRNA delivery in APP/PS1 mice with cognitive assays\",\n      \"pmids\": [\"36412210\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How AP2S1 mechanistically controls LE-lysosome fusion is undefined\", \"Relationship between this role and canonical AP2 function unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Extended the cargo-adaptor mechanism beyond Arg15 by showing additional surface residues are required for AP2 complex assembly and general clathrin-mediated endocytosis.\",\n      \"evidence\": \"Transferrin uptake CME assay, Co-IP of AP2 subunits, and quantitative interaction proteomics (preprint)\",\n      \"pmids\": [\"bio_10.1101_2024.07.22.24310683\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint not yet peer-reviewed\", \"Functional role of the intersectin-1 interaction not validated\", \"Clinical correlation of these variants not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How AP2S1's canonical endocytic adaptor function and its endosome-lysosome fusion role are mechanistically coordinated, and the structural basis of cargo-motif recognition, remain open.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure of AP2σ2 bound to a cargo dileucine motif in the timeline\", \"Whether the APP/fusion role requires the assembled AP2 complex is unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 4, 6]},\n      {\"term_id\": \"GO:0038024\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [0, 6]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 4]}\n    ],\n    \"complexes\": [\"AP2 adaptor complex\"],\n    \"partners\": [\"AP2A1\", \"AP2B1\", \"AP2M1\", \"CASR\", \"VPS41\", \"ITSN1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}